title: Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study.
abstract: OBJECTIVE
  To define the optimal corticosteroid dose regimen in the initial treatment of temporal arteritis (TA).
  
  
  METHODS
  We conducted a retrospective long-term evaluation of the efficacy and toxicity of corticosteroid treatment in 77 TA patients treated with three different dose-regimens: group A starting at 30-40 mg/d of prednisone, group B > 40-60 mg/d, and group C > 60 mg/d.
  
  
  RESULTS
  The 3 patient groups were similar with regard to the mean age, male/female ratio, mean duration of follow-up, percentage of positive temporal artery biopsies, and rate of steroid tapering. There was a positive correlation between the starting dose and the cumulative dose of steroids at one year. Treatment efficacy was similar among the groups: cumulative cure rates (i.e. patients off steroids without exacerbation of TA for 6 months or more) were 11-13%, 29-35%, and 48-50% after 1, 2, and 3 years, respectively. In addition, the rates of disease flare were similar among the groups after 3 years of follow up, although group C patients tended to have fewer TA exacerbations during the first year compared to the other groups. In contrast, group A patients developed significantly fewer steroid side effects: 36% compared to 78% and 88% in groups B and C.
  
  
  CONCLUSIONS
  The group A steroid regimen, starting with 30-40 mg/d and tapering to 10 mg/d within 6 months and to 5-7.5 mg/d within 1 year, was effective and less toxic in this patient population, than the two higher dose regimens.
authors.affiliation: Rheumatology Service, Shaare-Zedek Medical Center, Jerusalem, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Nesher
authors.forename: A
authors.initials: A
authors.lastname: Rubinow
authors.forename: M
authors.initials: M
authors.lastname: Sonnenblick
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D013700:Giant Cell Arteritis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone